[{"id":"c13367c4-1914-4e69-b5ef-4a4c4565814b","acronym":"DANUBE ","url":"https://clinicaltrials.gov/study/NCT02516241","created_at":"2021-01-17T17:19:50.756Z","updated_at":"2025-02-25T16:36:38.272Z","phase":"Phase 3","brief_title":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","source_id_and_acronym":"NCT02516241 - DANUBE ","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 underexpression • PD-L1 negative • PD-L1-L","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 underexpression • PD-L1 negative • PD-L1-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1126","initiation":"Initiation: 11/02/2015","start_date":" 11/02/2015","primary_txt":" Primary completion: 01/27/2020","primary_completion_date":" 01/27/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"cf51fac2-f996-42c3-ad9d-9fbe49593e74","acronym":"KEYNOTE-E90","url":"https://clinicaltrials.gov/study/NCT05872867","created_at":"2023-05-24T18:06:24.421Z","updated_at":"2025-02-25T16:18:49.806Z","phase":"Phase 1","brief_title":"Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)","source_id_and_acronym":"NCT05872867 - KEYNOTE-E90","lead_sponsor":"Wellmarker Bio","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 underexpression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • WM-A1-3389"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 03/14/2024","start_date":" 03/14/2024","primary_txt":" Primary completion: 02/22/2026","primary_completion_date":" 02/22/2026","study_txt":" Completion: 02/22/2026","study_completion_date":" 02/22/2026","last_update_posted":"2024-03-11"},{"id":"cd334664-b55d-49f3-960b-50fed3f6d9ca","acronym":" AcSé Pembrolizumab study","url":"https://clinicaltrials.gov/study/NCT03012620","created_at":"2021-01-18T14:49:27.880Z","updated_at":"2025-02-25T16:05:41.112Z","phase":"Phase 2","brief_title":"Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types","source_id_and_acronym":"NCT03012620 -  AcSé Pembrolizumab study","lead_sponsor":"UNICANCER","biomarkers":" AFP","pipe":" | ","alterations":" PD-L1 underexpression • FASN-L","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 underexpression • FASN-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 334","initiation":"Initiation: 07/05/2017","start_date":" 07/05/2017","primary_txt":" Primary completion: 12/26/2022","primary_completion_date":" 12/26/2022","study_txt":" Completion: 12/14/2023","study_completion_date":" 12/14/2023","last_update_posted":"2024-02-28"},{"id":"a9a4b065-a72c-4e31-861d-bbef6a0e8d93","acronym":"PEOPLE","url":"https://clinicaltrials.gov/study/NCT03447678","created_at":"2021-01-18T16:59:58.507Z","updated_at":"2024-07-02T16:36:29.303Z","phase":"Phase 2","brief_title":"Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.","source_id_and_acronym":"NCT03447678 - PEOPLE","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" EGFR • PD-L1 • ALK • CD8 • LAG3 • HAVCR2 • CD33 • TIGIT • GZMB • ITGAM • FOXP3","pipe":" | ","alterations":" PD-L1 expression • PD-L1 underexpression • PD-1 expression • ALK translocation • HAVCR2 expression • PD-L1-L • FOXP3 expression","tags":["EGFR • PD-L1 • ALK • CD8 • LAG3 • HAVCR2 • CD33 • TIGIT • GZMB • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 underexpression • PD-1 expression • ALK translocation • HAVCR2 expression • PD-L1-L • FOXP3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 05/23/2018","start_date":" 05/23/2018","primary_txt":" Primary completion: 05/31/2022","primary_completion_date":" 05/31/2022","study_txt":" Completion: 05/31/2022","study_completion_date":" 05/31/2022","last_update_posted":"2021-06-09"},{"id":"a98f7875-b404-43e2-89f7-8bc6e7a86796","acronym":"STUDY 1108","url":"https://clinicaltrials.gov/study/NCT01693562","created_at":"2021-01-17T17:37:48.396Z","updated_at":"2024-07-02T16:36:30.300Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study to Evaluate MEDI4736","source_id_and_acronym":"NCT01693562 - STUDY 1108","lead_sponsor":"MedImmune LLC","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 underexpression • PD-L1 negative • PD-L1-L","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 underexpression • PD-L1 negative • PD-L1-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Completed","enrollment":" Enrollment 1022","initiation":"Initiation: 09/05/2012","start_date":" 09/05/2012","primary_txt":" Primary completion: 02/28/2020","primary_completion_date":" 02/28/2020","study_txt":" Completion: 02/28/2020","study_completion_date":" 02/28/2020","last_update_posted":"2021-05-13"},{"id":"ed5a924d-bc0d-4e72-9bef-f6f733b2e045","acronym":"","url":"https://clinicaltrials.gov/study/NCT03495544","created_at":"2021-02-22T06:52:45.219Z","updated_at":"2024-07-02T16:37:11.579Z","phase":"","brief_title":"Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer","source_id_and_acronym":"NCT03495544","lead_sponsor":"Tatarstan Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression • PD-L1-L","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression • PD-L1-L"],"overall_status":"Unknown status","enrollment":" Enrollment 390","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 03/17/2019","primary_completion_date":" 03/17/2019","study_txt":" Completion: 07/01/2019","study_completion_date":" 07/01/2019","last_update_posted":"2018-04-12"}]